|

Celebrex for Back Pain
Celebrex for back pain is a popular brand name of the generic drug Celecoxib. It is also sold in some countries under the brand name Celebra. Celecoxib is a non-steroidal anti-inflammatory
drug
(NSAID). Celebrex is used to fight inflammation and relieve a variety of pain syndromes. Celebrex has similar pain relieving qualities to many OTC drugs such as
acetaminophen,
but it known for being particularly gentle on a patient’s gastrointestinal tract.

Risks of Celebrex
The majority of all NSAIDs share common risk factors and side effects including: mild gastrointestinal effects such as bloating, constipation, diarrhea, nausea and vomiting. Long term use of NSAIDs has also been linked to kidney problems. Celebrex was specifically designed to minimize stomach and intestinal discomfort in patients requiring a pain reliever long term.
Celebrex has also been linked to an increased risk of heart attack and stroke in some patients. There are ongoing studies to determine if this is a risk specific to certain types of non steroidal anti-inflammatory drugs, or the entire NSAID class as a whole.
Recommendation on Celebrex for Back Pain
Any drug that has any link to a severe health risk such as heart attack or stroke is not recommended. Why take a chance with your health? The pain relieving qualities of Celebrex are not much more effective than common OTC products which feature far less risk for serious health complications. If you have been taking Celebrex as a pain reliever, consider talking to your doctor about alternative treatment options for your symptoms. Better yet, consider a
holistic
non-pharmaceutical method that will have no side effects whatsoever. Remember, even if Celebrex works well for you, it is still a
symptomatic treatment
and will not cure your pain. Eventually, you should find a therapy option which will
cure
the underlying condition responsible for your symptoms, rather than covering it up with pharmaceutical relief.
Celebrex for Back Pain to Lower Back Pain Home page
9/12/07 Revised 6/5/08

|